• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Oral Contrast: Worth the Diagnostic Benefit?

Article

When faced with the possibility of missed findings, would patients generally agree to consuming oral contrasts?

Most outpatients would accept drinking oral contrast material if it has diagnostic benefit, according to a study published in the Journal of the American College of Radiology.

Researchers from University of Michigan in Ann Arbor performed a prospective survey to determine how patients valued the use of oral contrast material when undergoing abdominopelvic CT.

A total of 218 patients completed the survey, in which the subjects were given a hypothetical choice to not drink oral contrast. Eighty-nine percent of the subjects (193 patients) stated that they would always drink the contrast for fear of missing an important finding, and only 2% (5 patients) stated that they would never drink it regardless of risk.

Nine percent (20 patients) said that the decision to drink oral contrast would depend on the level of risk, with 8% (18 patients) indicating that they would accept a 0.01% to 1.00% risk for missing an important finding if they did not have to drink oral contrast.

The researchers also asked about the tolerability of the oral contrast; 55% (120 patients) rated the oral contrast taste as tolerable and 10% (21 patients) rated it bad or terrible.

Thirty-six subjects experienced concern or unease when they learned that they had to drink oral contrast:

8 minimal concern or unease

15 mild

10 moderate

3 extreme

Thirty-six patients experienced oral contrast–induced nausea or abdominal discomfort:

10 minimal

15 mild

10 moderate

1 extreme

The researchers concluded that most patients will drink oral contrast if it has any diagnostic benefit.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.